What pharma competitive intelligence is, and what it should deliver
Pharma competitive intelligence (CI) is the ongoing, legal collection and analysis of information about competing products, pipelines, prices, access deals and commercial activity, turned into decisions for your own brand: when to launch, how to position, where to deploy the field force and how to respond when a rival reads out data or wins a formulary. Good CI answers specific questions on a schedule. Bad CI is a monthly newsletter of press releases that nobody reads.
Most of what a mid-sized pharma or biotech company needs is already public: trial registrations, FDA approvals and exclusivity dates, payments to physicians, Medicare prescribing data, company filings and conference abstracts. The hard part is not finding it once. It is watching it continuously, linking it to your own data and getting the right insight to the right person before the decision is made.
This guide covers which public source answers which competitive question, how CI changes across the product lifecycle, how to automate monitoring, what to buy versus build versus outsource, how to judge a pharma competitive intelligence services provider, the ethical and legal lines, and when you do not need a vendor at all.
Which public source answers which competitive question
What is in their pipeline, and when will it read out?
ClinicalTrials.gov, run by the US National Library of Medicine, lists registered trials with design, endpoints, enrolment targets, sites and estimated completion dates. The EU Clinical Trials Information System covers European trials.
- Track status and date changes
- Compare endpoints with your own
- Site lists show where they recruit
When can a competitor or generic enter?
The FDA Orange Book lists patents and exclusivities for small-molecule drugs; the Purple Book does the same job for biologics and biosimilars. Drugs@FDA holds approval letters and labels.
- Patent and exclusivity expiry dates
- Biosimilar interchangeability status
- Label changes and new indications
Which physicians are they working with?
CMS Open Payments publishes payments from manufacturers to physicians, other prescribers and teaching hospitals, including consulting, speaking and research payments, each year.
- Speaker and consultant networks
- Therapy areas getting investment
- Research sites and investigators
Who is prescribing their product?
CMS publishes Medicare Part D prescriber data by provider and drug, showing claim counts and costs per prescriber for Medicare patients, with a lag of about two years.
- Prescriber concentration by region
- Specialties adopting a rival
- Free, if lagged, uptake view
How much are they investing, and where?
SEC EDGAR filings (10-K, 10-Q, 8-K) and earnings call transcripts show revenue by product, guidance, R&D spend, partnership terms and sales force changes for listed companies.
- Net revenue by brand by quarter
- Guidance and launch commentary
- Licensing and co-promotion deals
What are they about to say?
Conference abstracts and programmes (ASCO, ASH, ESMO, AAN and others), FDA advisory committee calendars and job postings signal data readouts, launch preparation and field force build-outs.
- Abstract titles before embargo lifts
- AdComm dates and briefing documents
- Hiring for reps, MSLs and market access
One free source most CI programmes underuse: CMS Open Payments
Competitive intelligence across the product lifecycle
Development
The questions are about competing mechanisms, trial endpoints and likely readout timing. CI feeds target product profiles, trial design choices and partnering decisions.
Pre-launch
Twelve to twenty-four months out, focus shifts to who launches first, likely labels, pricing corridors and which accounts and prescribers competitors are already cultivating.
Launch
In the first months the job is detecting competitor moves early: new messages, field force size, copay offers, formulary wins and early uptake by segment, then adjusting your own plan.
Mature and LOE
Later, CI watches patent challenges, biosimilar and generic filings, new indications for rivals and pricing pressure, and informs lifecycle management and resource shifts.
How to automate pharma competitive intelligence monitoring
Write the key intelligence questions
List the eight to fifteen questions leadership actually needs answered this year, for example when competitor X reads out phase 3, or whether competitor Y is building a field force in our specialty. Each question gets an owner and a deadline.
Map each question to sources
Assign the registries, FDA databases, filings, payments data and news feeds that answer each question, and decide how often each needs checking.
Automate collection
Pull structured sources through their public APIs or bulk downloads on a schedule, and monitor pages that change (trial records, label updates, press rooms) with change detection, so analysts read differences, not whole pages.
Link it to your own data
Match competitor prescribers, trial sites and paid speakers to your HCP master using NPI, so you can see overlap with your own targets and accounts.
Triage with rules and AI
Score each change against the intelligence questions, use AI to summarise long documents such as filings and trial updates, and route only relevant items to named people.
Publish and review
One competitor dashboard per brand, short alerts for urgent changes and a quarterly review of whether the questions are still the right ones.
Build, subscribe or outsource: how pharma companies source CI
Subscription databases
Providers such as Evaluate, Citeline, GlobalData and Clarivate sell curated pipeline, trial, deal and forecast databases. Strong for breadth across therapy areas; priced on quote and usually annual.
CI agencies
Specialist firms run conference coverage, expert interviews and bespoke landscape reports. Offshore research providers advertise low hourly rates (Flatworld Solutions lists pharma CI research from $14 an hour); specialist US and EU firms charge far more for senior analysts and primary research.
Built on your own data
Public sources are collected automatically, linked to your HCP master, CRM and prescription data, and published as dashboards and alerts in your own environment. Analysts spend their time on interpretation, not collection.
How to choose a pharma competitive intelligence services provider
The search results for this topic are full of provider lists and service menus. A menu does not tell you whether a firm can answer your questions. Ask these instead:
- Show us a deliverable for a brand like ours. Redacted is fine. Look for decisions and implications, not a summary of press releases.
- Which sources do you automate, and which do you check by hand? Manual checking of trial registries and labels misses changes between reports.
- Can you link competitor activity to our HCP and account data? CI that sits apart from your CRM and prescription data cannot tell you which of your targets a competitor is reaching.
- How fast do urgent items reach us? A topline readout or an FDA action needs same-day handling, not the next monthly report.
- How do you run primary research, and under what rules? Expect written ethics policies, identity disclosure in interviews and screening to avoid confidential information.
- What do we own at the end? Data, dashboards and source lists should stay with you if the contract ends.
On cost, the honest answer is that it varies by scope more than by vendor. Database subscriptions are quoted per seat and per module. Agency work ranges from low-cost offshore desk research to senior primary research priced per project. An automated monitoring build is a one-off data engineering project followed by a smaller running cost. Compare three-year totals for the questions you actually need answered, not day rates.
If your need is a one-off landscape before a launch or a deal, a project from a market research services team is enough. If you need continuous monitoring linked to your commercial data, our competitor analysis service builds it, using the same web scraping and data collection methods we use elsewhere, applied only to public sources.
Ethics, legal limits, common mistakes and when not to hire
Where the line is. The SCIP Code of Ethics, the most widely used standard for competitive intelligence practitioners, asks members to comply with all applicable laws and to disclose their identity and organisation before interviews. In the US, the Economic Espionage Act of 1996 makes theft of trade secrets a federal crime. In practice that rules out misrepresenting who you are to a competitor's employees, asking former employees for confidential information, accessing password-protected material without authorisation and using anything leaked. Public filings, registries, published payments, conference presentations and properly disclosed interviews are fair game. Brief your field force too: reps hear a lot, and they should report what HCPs volunteer, not solicit confidential competitor information.
Common mistakes:
- Collecting without questions. A feed of everything about every competitor buries the two items that matter.
- Treating trial registries as static. Changes to estimated completion dates, enrolment targets and endpoints are often the earliest signal, and they only show up if you track versions.
- Ignoring payments and prescribing data. Open Payments and Medicare Part D data show where competitors invest and who prescribes, for free.
- CI separated from forecasting. Competitor launch timing and uptake belong in your pharmaceutical forecast scenarios, not in a separate deck.
- No feedback loop. If nobody records which intelligence changed a decision, the programme cannot be improved or defended at budget time.
When you do not need a vendor: if you have one marketed product in a therapy area with few active competitors, a part-time analyst with automated alerts on the sources above covers most needs. If your question is about patient-level market dynamics rather than competitor actions, you need real-world data instead; our comparison of Komodo Health and IQVIA covers that choice. And if you are pre-launch, fold CI into your launch analytics plan rather than standing up a separate function.
How we work. Greenwolf Tech Labs is based in New Delhi with teams working US and European hours. Our founder Harsh Khubchandani spent his early career on specialty pharma commercial analytics at ZS Associates. We build automated monitoring on public sources, link it to your HCP and prescription data, and publish brand-level dashboards and alerts inside your own environment. For payments data specifically, our guide to Sunshine Act reporting explains how Open Payments records are structured. See our pharma commercial analytics service and the specialty pharmacy analytics hub for the wider commercial data work.
Questions about pharma competitive intelligence
What does competitive intelligence do in pharma?
What are the best free sources for pharma competitive intelligence?
How much do pharma competitive intelligence services cost?
Is competitive intelligence legal in pharma?
What is the difference between competitive intelligence and market research?
Can AI automate pharma competitive intelligence?
Should a mid-sized pharma company build CI in-house or outsource it?
Want competitor moves on your desk before they hit the news?
Tell us your brand, your main competitors and the decisions coming up. We will map the questions, the public sources that answer them and what automated monitoring would look like. Please do not send patient or prescriber-level data.
Part of our Market Research and Business Planning hub. Start with our market research services.